Idiopathic Short Stature Market By Product Type (Daily Recombinant Human Growth Hormone, Long-Acting Weekly Growth Hormone, Investigational Growth-Promoting Therapies); By Application (Treatment-Naïve Paediatric ISS Patients, Long-Term Maintenance Therapy, Daily-to-Weekly Growth Hormone Switching, Growth Hormone Combination Therapy); By End User (Paediatric Endocrinology Clinics, Hospitals, Specialty Clinics, Homecare Settings, Specialty Pharmacy and Patient Support Providers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Idiopathic Short Stature Market: Weekly Growth Hormone Redefines a Multi-Year, Payer-Filtered Treatment Category

The Global Idiopathic Short Stature Market was valued at USD 0.82 billion in 2025 and is projected to reach USD 1.28 billion by 2032, expanding at a CAGR of 6.6% during 2026–2032, according to Strategic Market Research.

 

Recombinant human growth hormone (rhGH) remains the primary FDA-approved therapy for Idiopathic Short Stature (ISS), helping improve growth outcomes and support children in achieving greater height potential. Recent innovations are focused on developing long-acting, once-weekly rhGH formulations to enhance convenience, adherence, and treatment experience. Additionally, ongoing clinical trials are evaluating combination therapies aimed at improving height velocity and optimizing final adult height outcomes. These advancements represent a shift toward more personalized and effective growth management strategies for children with ISS.

 

A Large Screening Pool Narrows Into a Select Treated Population

A large electronic-health-record study covering 189,280 patients aged six months to 20 years across 28 US primary-care practices identified 2,073 patients, or 1.1%, below the height threshold of −2.25 standard deviations. This threshold provides a starting point for clinical evaluation but does not establish a confirmed ISS diagnosis.

Applying the 1.1% rate to approximately 72.1 million US residents under 18 produces an illustrative screening pool of roughly 793,000 children. The calculation uses the US Census Bureau’s July 2025 population estimate of 341,784,857 and an under-18 share of 21.1%. The commercially relevant population becomes considerably smaller after clinical eligibility, remaining growth potential, specialist referral and payer approval are considered.

ISS is diagnosed after physicians exclude growth-hormone deficiency, genetic conditions, nutritional problems, chronic diseases, endocrine disorders and other identifiable causes of reduced growth. Further attrition occurs among children with limited severity, insufficient remaining growth potential, nearly closed growth plates, weak insurance coverage or low willingness to continue injections for several years.

Real-world registry evidence confirms that treated demand represents a fraction of the wider screening population. The US programme enrolled patients across an original network of 207 sites between 2002 and 2018. Among 12,660 paediatric patients included in effectiveness assessments, 2,367 had ISS, representing approximately 18.7% of the analysed cohort.

Treatment selection is also influenced by referral and family behaviour. Boys represented 74% of US growth-hormone recipients recorded as having ISS across four registries, while girls accounted for 26%. The underlying screening study found no comparable sex difference in the proportion falling below the height threshold, indicating that treatment expectations and referral patterns influence the treated population.

 

Weekly Therapy Creates the Strongest Near-Term Revenue Catalyst

Novo Nordisk’s Sogroya became the first once-weekly growth-hormone product with a US ISS indication in February 2026. The label covers children aged 2.5 years and older and provides instructions for patients switching from daily somatropin to weekly somapacitan. Its extended exposure reduces treatment frequency from more than 300 daily injections per year to approximately 52 weekly injections, an injection-frequency reduction of about 85.8%.

The pivotal ISS study included 88 treatment-naïve, prepubertal patients. Of these, 60 received weekly somapacitan and 28 received daily somatropin, representing 68.2% and 31.8% of study enrolment, respectively. Annualised height velocity at week 52 was 10.2 centimetres per year with weekly therapy and 10.5 centimetres with daily treatment. The 0.3-centimetre difference positions Sogroya around reduced treatment burden rather than superior one-year growth performance.

Families managing school schedules, travel and repeated injections may favour weekly administration, while physicians may consider it for newly diagnosed patients or children experiencing difficulties with daily treatment. Commercial adoption will depend on formulary placement, switching rules, rebates and evidence that fewer injections produce stronger persistence.

Novo Nordisk also retains Norditropin, giving the company daily and weekly positions within the US ISS pathway. This portfolio allows it to defend established prescribing relationships while targeting convenience-led switching. Some Sogroya growth may come from competing daily brands, while another portion may reflect migration within Novo Nordisk’s existing patient base.

Novo Nordisk’s wider rare-endocrine-disorder sales reached DKK 5.959 billion in 2025, increasing 19% in reported Danish kroner and 24% at constant exchange rates. Rare endocrine disorders contributed approximately 30.4% of the company’s DKK 19.608 billion rare-disease sales. These figures include several products and indications, but they demonstrate the commercial scale supporting Novo Nordisk’s daily-to-weekly growth-hormone strategy.

 

Daily Somatropin Maintains Its Established Market Position

Daily recombinant growth-hormone products continue to represent the incumbent treatment base. Humatrope, Norditropin, Genotropin and Omnitrope hold US ISS indications and benefit from physician familiarity, accumulated clinical evidence, specialty-pharmacy distribution, payer contracts and caregiver experience with existing injection devices.

The daily segment remains commercially resilient because switching a stable patient involves clinical, administrative and practical considerations. Families may prefer to continue with a familiar product when the growth response is satisfactory, while insurers may maintain daily somatropin as the preferred option when its negotiated cost is lower.

Pfizer’s Genotropin provides a direct measure of the global commercial scale of one established daily rhGH franchise. Pfizer reported USD 446 million in worldwide Genotropin revenue during 2025, down 5% from USD 470 million in 2024. US revenue declined 18% to USD 79 million, while international revenue decreased 2% to USD 367 million. Markets outside the US therefore contributed approximately 82.3% of 2025 Genotropin revenue, compared with 17.7% from the US. These revenues cover all Genotropin indications rather than ISS alone, but the results show the mature and geographically diversified position of daily rhGH therapy.

The 5% worldwide decline also shows the pressure facing established daily formulations as competitors introduce biosimilars, alternative devices and less-frequent administration. Weekly therapy must still provide enough practical value to justify a formulary change, price premium or new authorisation process. Market transition is therefore expected to occur through new-patient initiation and selective conversion rather than immediate replacement of daily products.

 

Patient-Year Economics Drive Market Value

The ISS market is more accurately measured through treated patient-years than diagnosis counts alone. Each initiated child may receive treatment for several years, generating recurring prescriptions, monitoring visits and repeated payer reviews.

Humatrope’s placebo-controlled ISS study reported a mean treatment duration of 3.7 years. This multi-year treatment period explains why persistence directly affects revenue. A child remaining on therapy for four years generates substantially more prescription value than a patient discontinuing during the first year.

Treatment timing also influences patient-year potential. Younger children generally have more remaining skeletal growth, giving clinicians a longer window to obtain a meaningful response. A South Korean multicentre study followed 578 prepubertal children with ISS, including 330 boys and 248 girls. Boys represented 57.1% of the cohort and girls 42.9%, a more balanced distribution than the US registry split. Earlier initiation, particularly before six years of age, was associated with a greater likelihood of reaching target height-standard-deviation outcomes.

Earlier diagnosis can therefore support both clinical benefit and a longer treatment duration. Referral delays, limited paediatric-endocrinology capacity and payer approval requirements can reduce this window by postponing initiation.

 

Reimbursement Controls the Conversion of Eligibility Into Revenue

FDA approval does not guarantee insurance coverage. Aetna’s published policy states that ISS may not be covered under some plans and applies requirements involving height severity, predicted adult height, growth-hormone testing and open epiphyses. Initial authorisation is generally limited to 12 months, making continuing revenue dependent on documented response and renewed eligibility.

A child treated for four years may therefore pass through four annual authorisation cycles. Families may abandon treatment during prior authorisation, physicians may avoid prescribing when approval appears unlikely, and patients may lose access during renewal. Insurance changes, inadequate response and dissatisfaction with progress can further reduce treatment duration.

Weekly products may lower treatment burden but do not remove reimbursement barriers. Insurers may request evidence that reduced injection frequency improves adherence, generates measurable value or offsets a higher net price. Sogroya currently demonstrates comparable one-year height velocity rather than superior adult-height outcomes, keeping rebates and preferred-product negotiations central to adoption.

Pricing pressure is stronger within the mature daily category, where several somatropin products compete for similar patients. The most commercially actionable subsegment is therefore not the entire diagnosed population but children who meet severity requirements, retain open growth plates, receive payer approval and have several potential treatment years remaining.

 

Regional Access Defines Uneven Commercial Potential

The United States is the most clearly commercialised ISS market because it combines several FDA-labelled daily products, paediatric-endocrinology infrastructure, specialty-pharmacy distribution and the February 2026 Sogroya indication. Its opportunity remains filtered by fragmented insurance policies, prior authorisation and varying predicted-height and renewal requirements.

South Korea shows strong expansion in the wider growth-hormone channel. Across all GH indications, treated patients increased from 13,789 in 2019 to 37,017 in 2023, while annual prescriptions rose from 95,262 to 267,330. Prescription expenditure increased from KRW 53.6 billion to KRW 144.0 billion, and the number of prescribing institutions rose from 250 to 398. Primary-care clinics increased their share of GH supply from 7.2% to 24.1%, while the share held by tertiary hospitals fell from 41.7% to 25.8%. These changes show that GH prescribing and dispensing are spreading beyond large specialist centres.

China adds a distinct domestic competitive layer. AnkeBio reported revenue of RMB 1.963 billion during the first nine months of 2025, up 2.15% year over year. Full-year revenue reached RMB 2.647 billion, increasing 4.36%. The company’s gene-engineering drug category generated RMB 1.937 billion, accounting for 73.2% of consolidated revenue and expanding 7.38%. This product category includes rhGH alongside other gene-engineered medicines, so it should not be treated as growth-hormone-only revenue.

AnkeBio’s annual report lists Ansomone human growth hormone as an approved treatment for ISS in China, directly connecting the company’s gene-engineering platform with the niche. Its presence strengthens domestic competition against multinational daily products and supports China’s position as an important manufacturing and commercial market for rhGH therapy.

European access remains narrower. ISS is not included among NICE’s routinely funded paediatric somatropin indications, while Sogroya’s EU indication covers growth-hormone deficiency rather than ISS. The EMA’s severe-ISS assessment of NutropinAq resulted in a negative opinion, reflecting the region’s cautious view of the benefit and value of pharmacological height improvement.

 

Pipeline Innovation Moves Beyond Daily and Weekly Somatropin

BioMarin is evaluating vosoritide in a Phase II study involving children with ISS. The study assesses several doses and includes a comparison with human growth hormone. Vosoritide follows a different bone-growth pathway and could provide an alternative for selected children if it demonstrates suitable safety and meaningful final-height benefit.

Development risk became more visible in March 2026 when BioMarin reported slipped capital femoral epiphysis events in investigator-sponsored studies involving several non-achondroplasia growth conditions. Enrolment and dosing were discontinued in Turner syndrome, SHOX deficiency and ACAN deficiency studies. The ISS programme continued for patients without ACAN deficiency, representing approximately 95% of enrolled ISS participants, with additional imaging requirements.

AnkeBio is also developing AK2017, a once-weekly recombinant human growth hormone-Fc fusion protein for ISS and other childhood growth disorders. Its 2025 annual report identifies the product as undergoing Phase III development and positions it as an upgrade to the company’s established Ansomone franchise. This programme could strengthen domestic competition in China by moving AnkeBio from a daily rhGH base towards long-acting therapy.

GeneScience Pharmaceuticals is evaluating GenSci134 in a Phase Ib/II programme comparing different dose levels with Norditropin in children with ISS. Alongside AK2017 and Sogroya, the programme reflects a wider competitive shift towards less-frequent administration.

Aromatase inhibitors such as letrozole have also been studied with growth hormone in adolescent boys to delay skeletal maturation and extend the remaining growth period. Their future commercial role depends on stronger long-term safety, final-height and reimbursement evidence.

 

Competitive Advantage Is Shifting Towards Treatment Experience

Novo Nordisk holds the broadest verified multinational position through daily Norditropin and weekly Sogroya. Its rare-endocrine sales growth of 24% at constant exchange rates provides a stronger commercial momentum signal than the declining 2025 performance of Pfizer’s Genotropin franchise. The comparison does not establish ISS market share because Novo Nordisk’s category covers multiple products and Pfizer’s Genotropin revenue covers several indications. It does, however, show contrasting trajectories between a portfolio benefiting from long-acting therapy and a mature daily product.

Eli Lilly’s Humatrope and Sandoz’s Omnitrope remain established daily competitors, while AnkeBio adds a China-focused ISS franchise through Ansomone and a Phase III weekly candidate. Company-level ISS revenue remains undisclosed, making regulatory coverage, administration frequency, geographic reach, formulary access, supply reliability and patient support more meaningful competitive indicators than unsupported product-share estimates.

 

Strategic Outlook: Persistence Will Decide the Winners

Weekly growth hormone represents the strongest near-term catalyst for the Idiopathic Short Stature Market. Its opportunity lies in newly diagnosed children, patients struggling with daily injections and selected switches from established somatropin brands.

Daily products will continue to generate the largest established treatment volume while insurers maintain preferred-brand contracts and physicians remain comfortable with familiar therapies. Pfizer’s USD 446 million Genotropin revenue demonstrates that mature daily rhGH products still support substantial global sales, even as the franchise faces declining revenue and competition from lower-frequency alternatives.

Novo Nordisk’s DKK 5.959 billion rare-endocrine business and AnkeBio’s RMB 1.937 billion gene-engineering drug category demonstrate the corporate resources behind long-acting development and market expansion. These broader company indicators reinforce the competitive importance of ISS without being treated as ISS-only revenue.

Longer-term growth may come from weekly and monthly growth-hormone candidates and therapies using alternative bone-growth pathways. Their contribution will depend on paediatric safety, meaningful final-height outcomes, regulatory approval and payer acceptance.

 

Idiopathic Short Stature Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.82 Billion
Revenue Forecast in 2032	USD 1.28 Billion
Overall Growth Rate	CAGR of 6.6% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Region
By Product Type	Daily Recombinant Human Growth Hormone, Long-Acting Weekly Growth Hormone, Investigational Growth-Promoting Therapies
By Application	Treatment-Naïve Paediatric ISS Patients, Long-Term Maintenance Therapy, Daily-to-Weekly Growth Hormone Switching, Growth Hormone Combination Therapy
By End User	Paediatric Endocrinology Clinics, Hospitals, Specialty Clinics, Homecare Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	• Increasing diagnosis and management of idiopathic short stature among paediatric populations. • Rising adoption of growth hormone therapies and long-acting treatment options. • Growing focus on improving treatment adherence through less frequent dosing approaches.
Customization Option	Available upon request